Predict your next investment

Setsuro Tech company logo
HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year



Series A | Alive

Total Raised


Last Raised

$4.93M | 2 yrs ago

About Setsuro Tech

Setsuro Tech is a biotechnology company that provides genome-edited mice and fertilized eggs with a genome editing method based on electroporation. The gene-editing technology has applications in a variety of fields, including drug discovery, animal husbandry, and textiles.

Setsuro Tech Headquarter Location

3-18-15 Kuramotochō Fujii Memorial Institute of Medical Sciences 5F

Tokushima, 770-0042,


+81 088-633-0233

Latest Setsuro Tech News

ERS Genomics and Setsuro Tech Sign CRISPR/Cas9 License Agreement

Mar 10, 2021

Nobel prize winning CRISPR technology to be applied in development of genetically engineered cell and animal models March 09, 2021 08:00 PM Eastern Standard Time DUBLIN & TOKUSHIMA, Japan--( BUSINESS WIRE )--ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Setsuro Tech, a biotechnology start-up using genome-editing techniques to develop and supply cell and animal models, today announced a non-exclusive license agreement granting Setsuro Tech access to ERS Genomics’ CRISPR/Cas9 patent portfolio for Japan. Setsuro Tech has developed a high-throughput genome editing method for mammalian embryos, termed genome editing by electroporation of Cas9 protein (GEEP). Using this method, the company is able to generate genetically engineered mice at low cost and in a short timeframe. Setsuro Tech is applying CRISPR/Cas9 technology to create genome-edited cell and animal models, based on end user requirements. ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform. “The versatility and programmability of Cas9 has enabled the CRISPR/Cas9 technology to become a revolutionary approach in biological research,” said Eric Rhodes, CEO of ERS Genomics. “We are pleased to support Setsuro Tech with this license agreement so that they are able to continue providing supportive tools and services for research activities.” “Our technology enables us to provide researchers with genome-edited models quickly and at relatively low cost,” commented Shinichiro Takezawa, CEO, Setsuro Tech. “The license from ERS expands our portfolio and having access to advanced technologies such as CRISPR/Cas9 will allow us to continue our high-quality offerings that combine CRISPR/Cas9 with our patent-pending technologies.” Financial details of the agreement are not disclosed. Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, is the exclusive agent for ERS Genomics in Japan. For high resolution images please contact Zyme Communications.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Setsuro Tech

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Setsuro Tech is included in 1 Expert Collection, including Biopharmaceuticals.



5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Setsuro Tech Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Setsuro Tech Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.